Late-Stage Cell Culture Process Optimization for Improved Antibody Productivity

Late-stage process optimization can provide an opportunity to improve the productivity of an established antibody manufacturing process while maintaining the product quality profile required for clinical development.

In this case, Protheragen supported a Phase II clinical-stage antibody program in its late-stage process optimization. The primary objective was to increase antibody expression as much as possible while maintaining product quality consistent with the established process.

By systematically reviewing historical process development reports and identifying the key areas suitable for further optimization, the cell culture process was refined to substantially improve antibody productivity. Following optimization, the expression level increased from 2.7 g/L to 4.7 g/L, representing an approximately 80% improvement, while the product quality profile remained consistent with the original process.

The Challenge

Increasing Productivity Without Altering Product Quality

The key challenge was to achieve a meaningful increase in antibody expression while ensuring that the optimized process continued to produce material with a product quality profile consistent with the established process.

For a clinical-stage antibody program, productivity improvement cannot be considered independently of product quality. Changes to cell culture conditions may affect not only antibody expression but also critical quality-related attributes.

Therefore, the optimization strategy needed to answer two questions simultaneously:

• How can antibody expression be further increased from the established process?
• How can product quality remain consistent with the original process after optimization?

The challenge was consequently not simply to maximize titer, but to identify an optimization window that could deliver higher productivity without compromising process consistency or product quality.

Our Strategy

• Review of Historical Process Development Data

Rather than immediately introducing broad experimental changes, the team first reviewed the historical process development reports and available process knowledge from the existing program.

This retrospective assessment helped identify previously investigated process parameters, development outcomes, and areas where further optimization could provide meaningful productivity gains.

By leveraging historical development knowledge, the team was able to focus subsequent optimization efforts on the most relevant process directions instead of repeating previously evaluated studies.

• Define the Key Optimization Direction

Based on the review of historical process development reports, the team identified the primary directions for late-stage process optimization.

The optimization strategy was designed around the existing process rather than replacing it with an entirely new development approach. This allowed the team to focus on improving productivity while keeping the established product quality profile as an important reference point.

The selected optimization direction was then evaluated against both expression performance and product quality, enabling productivity improvement to be assessed in the context of overall process performance.

• Evaluate Productivity and Product Quality Together

The optimization was not evaluated solely according to antibody titer.

The optimized process was compared with the original process to determine whether the increase in expression was accompanied by undesirable changes in product quality.

This integrated assessment allowed the team to identify an optimized process that achieved substantially higher antibody productivity while maintaining product quality consistent with the original process.

Results

Approximately 80% Increase in Antibody Productivity

The optimized cell culture process achieved an antibody expression level of 4.7 g/L, compared with 2.7 g/L under the original process.

This represents an approximately 80% increase in productivity.

Fig. 1. Comparison of antibody productivity and product quality-related results before and after cell culture process optimization.

Key Outcomes

Project Outcome

The project demonstrated that late-stage cell culture process optimization can deliver substantial productivity improvements without necessarily requiring a complete process redesign.

Through systematic review of historical process development information, the key optimization direction was identified and evaluated using both productivity and product quality as important decision criteria.

The optimized process increased antibody productivity from 2.7 g/L to 4.7 g/L, representing an approximately 80% improvement, while maintaining product quality consistent with the original process.

This case demonstrates the value of a data-driven, targeted optimization strategy for improving the productivity of established antibody cell culture processes during late-stage clinical development.

Related Services